Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor - Report - MDSpire

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor

  • By

  • Isabelle Panne

  • Matthias Matter

  • Jürg Vosbeck

  • Matthias von Rotz

  • Alexandra Steinemann

  • Marten Trendelenburg

  • Markus H. Heim

  • Peter Schirmacher

  • Andrea De Gottardi

  • Ansgar W. Lohse

  • Luigi M. Terracciano

  • Christine Bernsmeier

  • June 15, 2026

  • 0 min

Share

Clinical Report: Effective Management of Granulomatous Liver Disease Resembling Pyoderma Gangrenosum

Overview

This case study presents a 73-year-old man with isolated hepatic and ocular involvement of pyoderma gangrenosum without skin lesions. The patient achieved complete clinical and biochemical remission following treatment with a TNF-alpha inhibitor.

Background

Pyoderma gangrenosum is a rare autoimmune condition primarily affecting the skin, but it can present with extracutaneous manifestations, including hepatic involvement. Recognizing these atypical presentations is crucial for timely diagnosis and appropriate management, as they can mimic other serious conditions and lead to misdiagnosis.

Data Highlights

ParameterValueUpper Limit Normal (ULN)
AST128 U/L34 U/L
ALT116 U/L59 U/L
CRP147.5 mg/L10 mg/L

Key Findings

  • The patient presented with fever, weight loss, and elevated liver enzymes.
  • Histological examination revealed sterile abscesses and granulomatous inflammation.
  • Extensive testing excluded common infectious and immunological causes.
  • Treatment with prednisone followed by infliximab led to symptom resolution.
  • This case highlights the systemic nature of pyoderma gangrenosum and the importance of considering it in differential diagnoses for granulomatous liver injury.

Clinical Implications

Clinicians should maintain a high index of suspicion for pyoderma gangrenosum in patients presenting with unexplained hepatic lesions, even in the absence of skin manifestations. Early recognition and treatment with TNF-alpha inhibitors may lead to significant clinical improvement.

Conclusion

This case underscores the need for awareness of extracutaneous manifestations of pyoderma gangrenosum and the potential for effective management with immunosuppressive therapies.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists
  2. Dermatology and Therapy, 2026 -- Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study
  3. Open Forum Infectious Diseases, 2023 -- Outpatient Dalbavancin Therapy Guided by Therapeutic Drug Monitoring for Inoperable Abscesses in Chronic Granulomatous Disease: A Case Study Over 11 Months
  4. PubMed, 2023 -- Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts
  5. PMC, 2016 -- Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial
  6. Concurrent Oral Pemphigus Vulgaris and Herpes Simplex Virus Infection in a Young Patient with Crohn’s Disease: A Unique Case of Oral Lesions During Anti-TNF Alpha and Immunomodulatory Treatment
  7. CDC Recommendations for Hepatitis B Virus Infection Screening and Testing
  8. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts - PubMed
  9. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial - PMC

Original Source(s)

Related Content